You have accessJournal of UrologyKidney Cancer: Evaluation and Staging I1 Apr 2010514 SFRP1 MRNA EXPRESSION IN RENAL CELL CANCER AND ONCOCYTOMA AND ASSOCIATION WITH CLINICOPATHOLOGICAL PARAMETERS Faranaz Atschekzei, Jörg Hennenlotter, Axel Merseburger, Sandra Waalkes, Hossein Tezval, Markus Kuczyk, and Jürgen Serth Faranaz AtschekzeiFaranaz Atschekzei Hannover, Germany More articles by this author , Jörg HennenlotterJörg Hennenlotter Tübingen, Germany More articles by this author , Axel MerseburgerAxel Merseburger Hannover, Germany More articles by this author , Sandra WaalkesSandra Waalkes Hannover, Germany More articles by this author , Hossein TezvalHossein Tezval Hannover, Germany More articles by this author , Markus KuczykMarkus Kuczyk Hannover, Germany More articles by this author , and Jürgen SerthJürgen Serth Hannover, Germany More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2010.02.590AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES SFRP1 is a member of the wnt pathway and loss of expression has been suggested to contribute to renal cell cancer (RCC) carcinogenesis. However, quantitative RNA expression data have so far only been obtained for a insignificant number of tumors and oncocytomas and it is not clear so far whether SFRP1 expression differs between malignant and benign tumors and a relationship of tumor progression and SFRP1 mRNA expression exists METHODS We quantitatively investigated 133 tumors (28 tumors with T1G1N0M0; 43 tumors with T1G>1N0M0, 29 tumors with T3G<3M0N0 and 33 tumors with T3G3 or N>0 or M>0), 125 peritumoral samples, 18 oncocytomas and 13 paired peritumoral samples for SFRP1 RNA expression analysis using real-time PCR. For relative quantitation four endogenous controls were combined and the delta-delta Ct method were applied. RESULTS Comparing tumoral and peritumoral tissue groups a 31 fold (p<0.000001) and 23 fold (p<0.000001) reduction of SFRP1 mRNA expression was determined in clear cell RCC (ccRCC) and oncocytoma, respectively. Relative SFRP1 quantitation analyis allowed discrimination of tumor and peritumoral cells in ccRCC samples with an AUC value of 0.98(95% CI 0.96 - 1.00) in ROC analysis. Statistical comparison of SFRP1 RNA expression with clinical stage of tumors revealed no statistical significant relationship. CONCLUSIONS Significant loss of SFRP1-expression occurs in most of ccRCC and oncocytomas thus limiting the differential diagnostic value of SFRP1 mRNA quantitation in kidney tumors. In fact, our data support the hypothesis that SFRP1 mediated wnt pathway changes are frequent and early events in kidney tumorigenesis considering that a signifcant loss of SFRP expression is detected in both malignant and benign tumors. © 2010 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 183Issue 4SApril 2010Page: e203 Peer Review Report Advertisement Copyright & Permissions© 2010 by American Urological Association Education and Research, Inc.MetricsAuthor Information Faranaz Atschekzei Hannover, Germany More articles by this author Jörg Hennenlotter Tübingen, Germany More articles by this author Axel Merseburger Hannover, Germany More articles by this author Sandra Waalkes Hannover, Germany More articles by this author Hossein Tezval Hannover, Germany More articles by this author Markus Kuczyk Hannover, Germany More articles by this author Jürgen Serth Hannover, Germany More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...